Genmab (GMAB) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Biotech company Genmab reported impressive net sales of $3,016 million for its cancer treatment DARZALEX in the third quarter of 2024, with strong performance both in the U.S. and globally. The company benefits from royalties on these sales, which are managed through a licensing agreement with Janssen Biotech.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
